Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech

Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech companies 


LAUSANNE, Switzerland, September 10, 2020

Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, announced it has been recognized as one of the Top 100 Swiss Startup companies during the 2020 award ceremony and ranked within the Top 10 Biotech companies. The winners were selected by a jury of 100 leading startup experts and investors and announced during the award ceremony held on September 9, 2020 in Zurich. 

The inclusion of Oculis in this prestigious list reflects the significant progress the Company has made during 2020. In February, the Company announced positive results from a Phase 2 clinical trial of its novel topical therapeutic candidate OCS-01 in patients with Diabetic Macular Edema. In May, the Company reported positive data from a second Phase 2 trial (SKYGGN) with OCS-01 for treating Inflammation and Pain following cataract surgery. In July, the Company reported a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on both indications for OCS-01 and confirmed it was planning Phase 3 programs to further investigate the potential of OCS-01. These trials are expected to start in 2021. In addition, Oculis continues its very innovative approach with OCS-02 a topical anti-TNF alpha, and potentially a first in class steroid-sparing treatment for anterior uveitis and dry eye disease. It may also open the doors to personalized treatment for Dry Eye Syndrome, thanks to the identification of a potential genetic biomarker of treatment response. 

Oculis has also strengthened its senior leadership team significantly over the year, with the appointments of Dr. Marcia de Souza Lima as Chief Medical Officer, Dr. Frédéric Pilotaz as Vice President of Technology & Pharmaceutical Sciences and Dr. David Bingaman as Vice President, Global Clinical Development. Most recently, Oculis announced its U.S. expansion and the appointment of Sylvia Cheung as Chief Financial Officer, who joins the company from the NASDAQ-listed company Anika Therapeutics. 

About the Top 100 Swiss Startup Award The TOP 100 Swiss Startup Award has become a benchmark in Switzerland’s startup ecosystem: In the last 10 years, the event has featured 397 startups that have created more than 8,700 jobs and raised CHF 4.2 billion. Forty-two exits and two IPOs top off the achievements so far. Each year since 2011, the 100 most innovative and promising Swiss startups are picked by a jury of 100 leading investors and startup experts. http://www.top100startups.swiss/ 

About Oculis

Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients.

Oculis’ novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.

The Company’s leading clinical candidates include OCS-01 and OCS-02:

• OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone based on Oculis’ proprietary Solubilizing Nanoparticle (SNP) technology. OCS-01 is moving to Phase 3 in two indications – Diabetic Macular Edema (DME) and post-ocular surgery – following a positive End-of-Phase 2 meeting with FDA. OCS-01 has the potential to provide the first non-invasive topical treatment option for DME patients and the first once a day, preservative free steroid for inflammation and pain following ocular surgery.

• OCS-02 is a novel topical anti-TNF alpha antibody. It has successfully completed two proof-of-concept clinical trials in Acute Anterior Uveitis and in Dry Eye Disease and is progressing into Phase 2b.

In addition, Oculis’ formulation discovery focus and capabilities are enabling the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.

Oculis has an experienced management team from global ophthalmic companies and is supported by leading international life science investors. Oculis is headquartered in Lausanne, Switzerland, with research operations in Iceland and U.S. operations in Boston, MA.

To learn more visit www.oculis.com



Dr. Riad Sherif, CEO

Louie-Anne Gauthier, VP Strategic Marketing, BD&L

Investor Relations

Burns McClellan
John Grimaldi
212-213-0006 x362

Media relations

Citigate Dewe Rogerson
Mark Swallow / Sylvie Berrebi
+44 7903 737703 / +44 7714 306525